Research Journal of Medical Sciences
ISSN: Online 1993-6095ISSN: Print 1815-9346
Abstract
The study aimed to determine the anatomical and functional results of intravitreal bevacizumab (IVB) in patients with macular edema due to retinal vascular occlusion (RVO). The study was conducted at Department of Ophthalmology of Era’s Lucknow Medical College and Hospitals. In this retrospective observational study, 98 Patients with branch or central BRVO (BRVO/CRVO) and ME were enrolled. Bevacizumab (1.25 mg) was injected into the vitreous of all patients and they were followed for three months. Best‐corrected visual acuity (BCVA) quantified with Log MAR and central macular thickness (CMT) with optical coherence tomography (OCT) were measured at baseline, 1 month and 3 months. Results were analyzed within BRVO and CRVO groups and with reinjection frequency. The average age was 58.3±12.4 years and 55.1% were male. BRVO was detected in 63.3% and CRVO in 36.7% of patients. Mean CMT decreased significantly from a baseline level (480±110 μm) to 1 (275±95 μm) and 3 months (260±85 μm) after treatment (p<0.001). The mean BCVA significantly increased from 1.1±0.4 LogMAR at baseline to 0.65±0.3 and 0.60±0.35 at 1 and 3 months, respectively (p<0.001). 3 months BRVO patients had better anatomic and visual improvements compared to CRVO patients (p<0.01, ). The result was better when patients received two or more injections than when they received only one injection. Bevacizumab given intravitreally is safe and effective in reducing macular edema and improving VA in patients with RVO. The early and repetitive course has a better result, especially in cases of BRVO. This study results corroborate the value of bevacizumab as one of the most economical treatment modality in RVO disease.
How to cite this article:
Anoop Mishra. Clinical Evaluation of Intravitreal Bevacizumab in Patients with Macular Edema Secondary to Retinal Vein Occlusion: A 3‐Month Follow‐Up Study.
DOI: https://doi.org/10.36478/makrjms.2018.98.104
URL: https://www.makhillpublications.co/view-article/1815-9346/makrjms.2018.98.104